Group 1 - The core point of the news is that the controlling shareholder of Rejing Bio, Lin Changqing, plans to reduce his shareholding due to personal funding needs, which will not affect the company's control or stable operations significantly [1] - Lin Changqing intends to reduce his holdings by up to 1,000,000 shares, representing 1.0787% of the total share capital, through centralized bidding and block trading [1] - As of the announcement date, Lin Changqing holds 21,682,487 shares, accounting for 23.39% of the company's total shares [1] Group 2 - In 2024, Rejing Bio reported total revenue of 51,089.06 million yuan, a decrease of 7.62% year-on-year [3] - The net profit attributable to the parent company was -17,923.07 million yuan, compared to a profit of 2,851.62 million yuan in the same period of 2023 [3] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 30, 2019, with an issuance of 15,550,000 shares at a price of 29.46 yuan per share [3]
热景生物实控人拟减持 实控人方6月份完成套现2.14亿